Reasons for Discontinuation of Ruxolitinib and Outcomes Among Patients With Myelofibrosis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Life After Ruxolitinib: Reasons for Discontinuation, Impact of Disease Phase, and Outcomes in 218 Patients With Myelofibrosis
Cancer 2019 Dec 20;[EPub Ahead of Print], F Palandri, M Breccia, M Bonifacio, N Polverelli, EM Elli, G Benevolo, M Tiribelli, E Abruzzese, A Iurlo, FH Heidel, M Bergamaschi, A Tieghi, M Crugnola, F Cavazzini, G Binotto, A Isidori, N Sgherza, C Bosi, B Martino, R Latagliata, G Auteri, L Scaffidi, D Griguolo, M Trawinska, D Cattaneo, L Catani, M Krampera, RM Lemoli, A Cuneo, G Semenzato, R Foà, F Di Raimondo, D Bartoletti, M Cavo, GA Palumbo, N VianelliFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.